RxDoctor Payments DataLook up a doctor →

Stuart Shoengold, MD

Urology · Millburn, NJNPI 1689689275

Payments from drug & device makers

$95,539in general payments, 2019–2025

Across 404 payments — averaging $236.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Valencia Technologies Corporation$51K
  • Ferring Pharmaceuticals Inc.$9K
  • Astellas Pharma US Inc$8K
  • Antares Pharma, Inc.$5K
  • Pfizer$5K
  • AbbVie$4K
  • plus $14K from 47 others
$355in research payments, 2019–2025

Across 1 payment — averaging $355.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$355

What the payments were for

  • Consulting fees$1,1102%
  • Speaking & faculty fees$26,75559%
  • Travel & lodging$4,76810%
  • Food & beverage$12,37527%
  • Education$5281%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$95,539 in reported general payments places this provider in the 90th percentile of 401 urology providers in New Jersey.

See all urology providers in New Jersey

Medicare billing

Part B allowed, 2024
$422,656
Medicare patients
557
Services billed
16,261

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide25$349,049
XtandiEnzalutamide24$339,941
NubeqaDarolutamide18$243,606
MyrbetriqMirabegron337$195,066
GemtesaVibegron238$166,368
OrgovyxRelugolix23$75,233
Abiraterone Acetate35$34,194
Testosterone129$18,567
XyostedTestosterone Enanthate24$14,537
Tamsulosin Hcl742$8,128
Mirabegron ErMirabegron13$7,520
Solifenacin Succinate117$6,192
Potassium Citrate ErPotassium Citrate98$5,855
Bethanechol Chloride64$5,852
Estradiol70$4,765

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$7,636$535,007361 claims
Johnson & JohnsonErleada$2,317$349,04925 claims
BayerNubeqa$775$243,60618 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$140$241,601261 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$154$34,19435 claims
Antares Pharma, Inc.Xyosted$4,706$14,53724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 401 urology providers in New Jersey.

Other urology in Millburn

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →